HK1075215A1 - Thiazolidine carboxamide derivatives as modulators of the prostaglandin f receptor - Google Patents

Thiazolidine carboxamide derivatives as modulators of the prostaglandin f receptor

Info

Publication number
HK1075215A1
HK1075215A1 HK05109463.4A HK05109463A HK1075215A1 HK 1075215 A1 HK1075215 A1 HK 1075215A1 HK 05109463 A HK05109463 A HK 05109463A HK 1075215 A1 HK1075215 A1 HK 1075215A1
Authority
HK
Hong Kong
Prior art keywords
prostaglandin
modulators
receptor
carboxamide derivatives
thiazolidine carboxamide
Prior art date
Application number
HK05109463.4A
Other languages
English (en)
Inventor
Page Patrick
Jorand-Lebrun Catherine
Quattropani Anna
Pomel Vincent
Schwarz Matthias
Hamelin Estelle
Russell J Thomas
Original Assignee
Serono Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Serono Lab filed Critical Serono Lab
Publication of HK1075215A1 publication Critical patent/HK1075215A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/04—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D277/06—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Pyrrole Compounds (AREA)
HK05109463.4A 2002-03-28 2005-10-24 Thiazolidine carboxamide derivatives as modulators of the prostaglandin f receptor HK1075215A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02100314 2002-03-28
PCT/EP2003/050083 WO2003082278A1 (en) 2002-03-28 2003-03-27 Thiazolidine carboxamide derivatives as modulators of the prostaglandin f receptor

Publications (1)

Publication Number Publication Date
HK1075215A1 true HK1075215A1 (en) 2005-12-09

Family

ID=28459561

Family Applications (1)

Application Number Title Priority Date Filing Date
HK05109463.4A HK1075215A1 (en) 2002-03-28 2005-10-24 Thiazolidine carboxamide derivatives as modulators of the prostaglandin f receptor

Country Status (22)

Country Link
US (2) US20050215605A1 (sr)
EP (1) EP1487442B1 (sr)
JP (1) JP4602672B2 (sr)
KR (1) KR20040095311A (sr)
CN (1) CN100484524C (sr)
AT (1) ATE489951T1 (sr)
AU (2) AU2003240757B2 (sr)
BR (1) BR0308748A (sr)
CA (1) CA2477265A1 (sr)
DE (1) DE60335175D1 (sr)
EA (1) EA007328B1 (sr)
ES (1) ES2360882T3 (sr)
HK (1) HK1075215A1 (sr)
HR (1) HRP20040759A2 (sr)
IL (1) IL164212A0 (sr)
MX (1) MXPA04009374A (sr)
NO (1) NO20044262L (sr)
PL (1) PL372919A1 (sr)
RS (1) RS81604A (sr)
UA (1) UA78021C2 (sr)
WO (1) WO2003082278A1 (sr)
ZA (1) ZA200406763B (sr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL372919A1 (en) * 2002-03-28 2005-08-08 Applied Research Systems Ars Holding N.V. Thiazolidine carboxamide derivatives as modulators of the prostaglandin f receptor
WO2004064730A2 (en) 2003-01-14 2004-08-05 Cytokinetics, Inc. Compounds, compositions and methods
MY150129A (en) * 2004-04-09 2013-11-29 Archer Daniels Midland Co Method of preparing fatty acid alkyl esters from waste or recycled fatty acid stock
TWI359812B (en) 2004-06-17 2012-03-11 Cytokinetics Inc Compounds, compositions and methods
US7176222B2 (en) 2004-07-27 2007-02-13 Cytokinetics, Inc. Syntheses of ureas
US7825120B2 (en) 2005-12-15 2010-11-02 Cytokinetics, Inc. Certain substituted ((piperazin-1-ylmethyl)benzyl)ureas
TW200808321A (en) 2005-12-15 2008-02-16 Cytokinetics Inc Certain chemical entities, compositions and methods
WO2007078815A2 (en) 2005-12-16 2007-07-12 Cytokinetics, Inc. Certain chemical entities, compositions, and methods
JP5178526B2 (ja) 2005-12-19 2013-04-10 サイトキネティクス・インコーポレーテッド 化合物、組成物および方法
CN102391237B (zh) * 2006-02-07 2014-07-16 株式会社·R-技术上野 用于制备前列腺素衍生物的方法
US20090163586A1 (en) 2007-12-20 2009-06-25 Astrazeneca Ab Bis-(Sulfonylamino) Derivatives in Therapy 205
CA2769512C (en) * 2009-07-29 2019-07-09 Duke University Compositions comprising fp receptor antagonists and their use for inhibiting hair growth
JP2014527511A (ja) 2011-06-24 2014-10-16 アムジエン・インコーポレーテツド Ｔｒｐｍ８拮抗剤及び治療におけるそれらの使用
WO2012177896A1 (en) 2011-06-24 2012-12-27 Amgen Inc. Trpm8 antagonists and their use in treatments
US8952009B2 (en) 2012-08-06 2015-02-10 Amgen Inc. Chroman derivatives as TRPM8 inhibitors
US20160264536A1 (en) 2013-10-23 2016-09-15 Takeda Pharmaceutical Company Limited Heterocyclic compound
US9447055B1 (en) 2016-01-04 2016-09-20 Merck Serono S.A. α-amino esters of hydroxypropylthiazolidine carboxamide derivative and salt form, crystal polymorph thereof
US10555934B2 (en) * 2016-01-04 2020-02-11 ObsEva S.A. Alpha-amino esters of hydroxypropylthiazolidine carboxamide derivative and salt form, crystal polymorph thereof
AU2017205670B2 (en) * 2016-01-04 2021-05-20 Merck Serono S.A. L-valinate of hydroxypropylthiazolidine carboxamide derivative and salt form, crystal polymorph thereof
EA039545B1 (ru) * 2016-10-13 2022-02-09 Обсева С.А. Способы предотвращения преждевременных родов с помощью комбинации ингибитора pgf2 и токолитического агента
US11289654B2 (en) 2016-12-22 2022-03-29 Guangzhou Chinaray Optoelectronic Materials Ltd. Polymers containing furanyl crosslinkable groups and uses thereof
US11534428B1 (en) 2018-05-16 2022-12-27 Xoma (Us) Llc Compositions and methods for delaying the incidence of labor
WO2022101495A1 (en) 2020-11-16 2022-05-19 ObsEva S.A. Compositions and methods for the treatment or prevention of preterm labor
CA3204921A1 (en) * 2020-12-11 2022-06-16 Elise A. Olsen Compositions and methods for inhibiting hair growth

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4016270A (en) * 1975-10-31 1977-04-05 Alza Corporation Method for treating dysmenorrhea with a uterine therapeutic system
JPH0662529B2 (ja) * 1984-07-13 1994-08-17 三共株式会社 アミノ酸誘導体
JPS6450818A (en) * 1987-08-20 1989-02-27 Tsumura & Co Prostaglandin f2alpha-inhibitor
US5338755A (en) * 1990-07-31 1994-08-16 Elf Sanofi N-sulfonylindoline derivatives, their preparation and the pharmaceutical compositions in which they are present
US6271201B1 (en) * 1993-07-15 2001-08-07 Board Of Regents, The University Of Texas System Methods for the selective regulation of placental prostanoids and inhibition of labor using IGF-I
TR199900383T2 (xx) * 1996-08-28 1999-05-21 The Procter & Gamble Company 1,3-Diheterosiklik metaloproteaz inhibit�rleri.
BR9811573A (pt) * 1997-07-31 2000-09-19 Elan Pharm Inc Compostos de benzila que inibem a adesão de leucócitos mediada por vla-4
AR016133A1 (es) * 1997-07-31 2001-06-20 Wyeth Corp Compuesto de carbamiloxi que inhiben la adhesion de leucocitos mediada por vla-4, compuestos que son prodrogas de dichos compuestos, composicionfarmaceutica, metodo para fijar vla-4 a una muestra biologica, metodo para el tratamiento de una condicion inflamatoria
US6645939B1 (en) * 1997-11-24 2003-11-11 Merck & Co., Inc. Substituted β-alanine derivatives as cell adhesion inhibitors
PL372919A1 (en) * 2002-03-28 2005-08-08 Applied Research Systems Ars Holding N.V. Thiazolidine carboxamide derivatives as modulators of the prostaglandin f receptor

Also Published As

Publication number Publication date
DE60335175D1 (de) 2011-01-13
EP1487442B1 (en) 2010-12-01
IL164212A0 (en) 2005-12-18
WO2003082278A1 (en) 2003-10-09
US8415480B2 (en) 2013-04-09
CN1655780A (zh) 2005-08-17
JP4602672B2 (ja) 2010-12-22
US20080255094A1 (en) 2008-10-16
KR20040095311A (ko) 2004-11-12
PL372919A1 (en) 2005-08-08
AU2003240757B2 (en) 2008-07-03
BR0308748A (pt) 2005-01-11
CN100484524C (zh) 2009-05-06
EA200401270A1 (ru) 2005-02-24
UA78021C2 (en) 2007-02-15
JP2005531524A (ja) 2005-10-20
EP1487442A1 (en) 2004-12-22
US20090215749A9 (en) 2009-08-27
RS81604A (en) 2006-12-15
NO20044262L (no) 2004-10-07
AU2003240757A1 (en) 2003-10-13
US20050215605A1 (en) 2005-09-29
CA2477265A1 (en) 2003-10-09
HRP20040759A2 (en) 2004-12-31
ATE489951T1 (de) 2010-12-15
MXPA04009374A (es) 2005-01-25
ES2360882T3 (es) 2011-06-10
EA007328B1 (ru) 2006-08-25
AU2008207407A1 (en) 2008-09-11
ZA200406763B (en) 2005-09-30

Similar Documents

Publication Publication Date Title
HK1075215A1 (en) Thiazolidine carboxamide derivatives as modulators of the prostaglandin f receptor
NO20053991L (no) Piperazin-2-karboksamidderivater
MXPA05013366A (es) Derivados de benzazepina utiles para el tratamiento de enfermedades asociadas con el receptor 5ht2c.
RS20050104A (en) Indole or benzimidazole derivatives for modulating ikb kinase
NO20073465L (no) Benzotiazol-derivater
MX2007000505A (es) Derivados de oxindol sustituidos y medicamentos que contienen los mismos.
MY135841A (en) Novel benzodioxoles
TW200510334A (en) Preraration and use of aryl alkyl acid derivatives for the treatment of obesity
MXPA03010232A (es) Compuestos de arilsulfonamida, para el tratamiento de la obesidad, de la diabetes tipo ii y de trastornos del sistema nervioso central.
MXPA05011707A (es) Dihidroquinazolinas sustituidas con propiedades antivirales.
HK1069169A1 (en) Substituted tetracyclic pyrroloquinolone derivatives useful as phosphodiesterase inhibitors
NO20062417L (no) N-tiazol-2-yl-benzamidderivater
MXPA04005886A (es) Derivados de azaindolilalquilamina como ligandos de 5-hidroxitirptamina-6.
MXPA05007115A (es) Nuevos agonistas inversos del receptor cb 1.
HK1075664A1 (en) Piperazine benzothiazoles as agents for the treatment of cerebral ischemic disorders or cns disorders
ZA200404752B (en) 6-aminomorphinane derivatives method for the production and use thereof
MY141528A (en) Anilinopyrazole derivatives useful for the treatment of diabetes
NO20082214L (no) 1,1-Diokso-tiomorfolinyl-indolyl-metanonderivater for anvendelse som H3-modulatorer
IL161047A0 (en) Pyrazole derivatives for increasing endogenous testosterone levels
IL161116A (en) Use of irbesartan for the preparation of medicinal products that are useful for preventing or treating pulmonary arterial hypertension
MXPA04001977A (es) Antagonistas v de receptor ccr-3.
RS20050421A (en) Aminoindazole derivatives and use thereof as kinase inhibitors
RS20060622A (en) Indol-2-one derivatives for the treatment of central nervous disorders, gastrointestinal disorders and cardiovascular disorders
YU89903A (sh) Derivati oksazola koji su supstituisani karboksilnom kiselinom za primenu kao ppar-alfa i -gama aktivatori u lečenju dijabetesa

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20220327